论文部分内容阅读
目的:探讨密固达治疗绝经后骨质疏松症(PMO)患者的疗效。方法:回顾性分析21例PMO患者首次给予密固达治疗后的疗效,通过电话随访和复诊12个月,比较患者治疗前后的疼痛评分情况、骨密度的改变以及不良反应。结果:治疗后3、6、12个月与治疗前相比,疼痛评分明显降低,差异有统计学意义(P<0.05);治疗后12个月腰椎与股骨颈WARD三角区的骨密度与治疗前相比均有显著提高(P<0.05);所有患者在用药过程中均无严重不良反应发生。结论:密固达治疗PMO疗效可靠且安全性高,值得临床推广应用。
Objective: To investigate the effect of Miugunda in the treatment of postmenopausal osteoporosis (PMO). Methods: The clinical data of 21 patients with PMO were retrospectively analyzed. The results of pain score, bone mineral density and adverse reactions before and after treatment were compared by telephone follow-up and follow-up for 12 months. Results: The scores of pain at 3, 6 and 12 months after treatment were significantly lower than those before treatment (P <0.05). The BMD and treatment of the WARD triangle at lumbar and femoral neck at 12 months after treatment (P <0.05). All patients had no serious adverse reactions during the course of medication. Conclusion: The solid-based treatment of PMO reliable and safe, it is worth clinical application.